Ther. Deliv.(2014) 5 (3) 240 future science group in the development of clinically relevant
ASO platforms [6]. The constrained ethyl/phosphorothiote modifications improve serum …

Chemically synthesized, small interfering RNAs (siRNA) are currently used as a new class of
therapeutic molecules, allowing the controlled down-regulation of pathologically relevant …

The main objective was to determine whether a pool of small interfering RNAs (siRNAs)
targeting different regions of hepatitis B virus surface antigen (HBsAg) efficiently inhibits …

Chronic infection with the hepatitis B virus (HBV) remains a significant worldwide medical
problem. While diseases caused by HIV infection, tuberculosis and malaria are on the …

RNA interference (RNAi) offers the potential to treat disease at the earliest onset by
selectively turning off the expression of target genes, such as intracellular oncogenes that …

3057 Background: Atu027 is a novel RNAi therapeutic based on cationic lipoplexes
containing chemically stabilized siRNAs, which targets PKN3 gene expression in the …

Background: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-
related deaths worldwide. Stathmin 1 (STMN1) suppression was reported to reduce cellular …

Inhibiting specific gene expression with siRNA provides a new therapeutic strategy to tackle
many diseases at the molecular level. Recent strategies called high-density lipoprotein …

Long non-coding RNAs (lncRNAs) are defined as a class of RNA transcripts longer than 200
nucleotides encoded by mammalian genomes that lack protein-coding potential. LncRNA …

RNA interference (RNAi)-based therapeutics have the potential to treat chronic hepatitis B
virus (HBV) infection in a fundamentally different manner than current therapies. Using …